Q2 EPS Estimate for Nektar Therapeutics Lowered by Analyst

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at Zacks Research decreased their Q2 2025 EPS estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Monday, June 30th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of ($2.83) for the quarter, down from their previous forecast of ($0.19). The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics' Q3 2025 earnings at ($2.85) EPS, Q4 2025 earnings at ($2.86) EPS, Q1 2026 earnings at ($3.03) EPS, Q2 2026 earnings at ($3.59) EPS, Q3 2026 earnings at ($4.00) EPS, Q4 2026 earnings at ($4.10) EPS, FY2026 earnings at ($14.72) EPS, Q1 2027 earnings at ($3.92) EPS, Q2 2027 earnings at ($4.46) EPS and FY2027 earnings at ($18.57) EPS.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). The business had revenue of $10.46 million for the quarter, compared to the consensus estimate of $15.61 million. Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. During the same quarter last year, the business posted ($2.70) EPS.

NKTR has been the topic of a number of other research reports. BTIG Research raised their price target on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, June 24th. Oppenheimer raised Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $90.00 target price on the stock in a research note on Friday, March 14th. Wall Street Zen cut Nektar Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, May 14th. Jefferies Financial Group upgraded shares of Nektar Therapeutics from a "hold" rating to a "buy" rating and boosted their price target for the company from $15.00 to $30.00 in a research report on Friday, April 11th. Finally, William Blair reissued a "market perform" rating on shares of Nektar Therapeutics in a research report on Monday, May 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Nektar Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $84.17.

Nektar Therapeutics Stock Performance

Shares of NKTR stock traded down $1.16 on Wednesday, hitting $24.37. 719,397 shares of the company's stock traded hands, compared to its average volume of 473,768. Nektar Therapeutics has a one year low of $6.48 and a one year high of $37.38. The company's fifty day simple moving average is $12.44 and its 200 day simple moving average is $12.43. The stock has a market capitalization of $302.43 million, a price-to-earnings ratio of -2.56 and a beta of 0.94.

Institutional Trading of Nektar Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Two Sigma Securities LLC raised its stake in shares of Nektar Therapeutics by 56.3% in the fourth quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 9,958 shares during the last quarter. Harvest Investment Services LLC purchased a new position in Nektar Therapeutics in the 4th quarter worth about $27,000. US Asset Management LLC purchased a new position in Nektar Therapeutics in the 4th quarter worth about $31,000. Algert Global LLC bought a new position in Nektar Therapeutics during the 1st quarter valued at about $33,000. Finally, US Bancorp DE boosted its holdings in shares of Nektar Therapeutics by 257.8% during the 1st quarter. US Bancorp DE now owns 50,085 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 36,085 shares during the last quarter. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.